Jun 8, 2022FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCCJERUSALEM, June 8, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
Jun 8, 2022Alpha Tau Announces Resignation of Gary Leibler from its Board of DirectorsJERUSALEM, June 7, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) (Nasdaq: DRTSW), ("Alpha Tau" or the "Company"), the developer of the...
May 26, 2022Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds-...
Mar 28, 2022Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds-...
Mar 22, 2022Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of DirectorsJERUSALEM, March 21, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha...